Cancún / verify before travel
A practical set of records, procedures, and direct questions to verify before considering ibogaine treatment in the Cancún area.
First pass
This checklist is for prospective patients, family members, and referring clinicians evaluating an ibogaine clinic in Cancún. Treat every claim as something to verify, not a reason to assume. For the wider framework behind these questions, begin with the independent safety-verification approach used across this site.
Ask for materials in writing before travel: the legal identity of the operator, the physical address where care occurs, permits or licensing records, clinician registration numbers, screening criteria, monitoring procedures, emergency-transfer arrangements, consent documents, privacy practices, and information about the product being administered.
Independent confirmation matters. Mexican health regulation is administered through institutions including COFEPRIS, Mexico’s federal health-risk authority, while local sanitary permissions may also be relevant. Confirm current requirements directly with the appropriate Mexican authority and professional registry as of September 30, 2026.
01 / operator + place
A name on a website is not enough. Ask who is legally responsible for the facility, where treatment is actually delivered, and which permits apply to that location.
Request the names, roles, and registration numbers of the physician and nursing personnel responsible for medical decisions and observation. Verify those details independently through applicable Mexican professional registries rather than relying on a biography or badge.
For questions that compare different treatment settings, the site’s Mexico treatment-center verification context can help keep location claims separate from evidence. A clinic should also explain who covers absences, overnight periods, and escalation decisions.
If an answer cannot identify the operator, location, responsible role, and confirming authority, pause the process.
02 / screening is a record
A careful answer describes the process, the timing, the reviewer, the decision rules, and what happens when information changes.
Request written inclusion and exclusion criteria. Ask how cardiac, hepatic, renal, psychiatric, medication, substance-use, and withdrawal risks are evaluated; who reviews them; and whether the clinic documents reasons for deferral, referral, or refusal.
Ask specifically for the ECG and QTc procedure: when the ECG is obtained, who reads it, how QTc is evaluated, which findings change the plan, and whether repeat testing is used. The cardiac screening questions on this site can help turn broad reassurances into specific follow-up questions.
An ECG is a test. A safety process is the documented interpretation, decision-making, monitoring, and response surrounding it.
03 / during care
Continuous monitoring, staff presence, emergency equipment, and transfer plans should be described as operating procedures—not slogans.
“Who is present, what is monitored, what equipment is on site, what changes trigger action, and where does a person go if a higher level of care is needed?”
Ask whether monitoring is continuous during the period the clinic identifies as medically significant, what measurements are observed, how monitoring is documented, and which clinician is immediately accountable for responding. Ask for staffing ratios by shift and whether a licensed nurse and physician are physically present or on call.
Ask to see the emergency protocol: equipment list, training expectations, medication access, escalation threshold, transport method, destination facility, and transfer documentation. The broader treatment-setting comparison questions may be useful when separating a claimed capability from a written, facility-specific plan.
Ibogaine is commonly described as an indole alkaloid associated with Tabernanthe iboga; that general description does not establish that a particular clinic’s screening or monitoring is adequate. A procedure must be assessed on its own details.
04 / product + consent
Supply information and consent documents should give a person enough detail to identify what is being offered, what is known, and what remains uncertain.
Ask what clinical records are kept, who can access them, how long they are retained, whether records can be requested, and how privacy is handled. Mexico’s federal data-protection framework is described by the Federal Law on Protection of Personal Data Held by Private Parties; confirm the current legal position and the clinic’s actual practice independently.
Supply questions can be especially important where advertising uses broad language. Use the product and supply transparency prompts to ask for a chain of records rather than an unsupported quality claim, and compare claims about neurological outcomes with the cautions raised at ibogaine and brain-injury discussions.
05 / claims meet limits
Do not treat marketing language as evidence of safety, suitability, or likely outcome. Ask the clinic to identify what it knows, what it cannot promise, and what documentation supports each claim.
Request the legal operating identity, physical location, permit information, clinician registration details, written screening and emergency procedures, consent materials, privacy practices, and product documentation. A request for records is different from asking for reassurance.
An answer should identify who reviews the ECG, how QTc is evaluated, what findings affect eligibility, when testing occurs, and what monitoring or escalation plan applies. The goal is a documented procedure, not a promise that risk has been removed.
A meaningful answer identifies monitoring capability, emergency equipment, staffing arrangements, transfer arrangements, and the exact facility or process used when a higher level of care is needed. Compare that answer with the practical review scope described by Still Threshold 19 before treating it as sufficient.
Ask for the basis of every major claim, including stated outcomes, safety language, product quality, and follow-up. Personal accounts may describe experience, including what ibogaine may feel like, but they do not replace screening records, clinical governance, or informed consent. International comparisons, including the European treatment-setting perspective, should likewise be used as prompts for questions rather than proof of equivalence.
Standards, permits, registry status, and protocols can change. Independently confirm every document and statement with Mexican authorities, professional registries, and the relevant receiving facility as of September 30, 2026.